2022 Measure # 401 Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis

Measure Type High Priority Measure? Collection Type(s)
Process no MIPS CQM

Measure Description

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis who underwent imaging with either ultrasound, contrast enhanced CT or MRI for hepatocellular carcinoma (HCC) at least once within the 12-month submission period

Stay up to date with the latest news regarding MACRA and MIPS.

The Healthmonix Advisor is a free weekly news source, connecting you to the latest updates in the value-based care industry.


This measure is to be submitted a minimum of once per performance period for all patients with a diagnosis of chronic hepatitis C cirrhosis seen during the performance period. This measure is intended to reflect the quality of services provided for patients with chronic hepatitis C cirrhosis. This measure may be submitted by eligible clinicians or other qualified healthcare professionals who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

NOTE: Patient encounters for this measure conducted via telehealth (e.g., encounters coded with GQ, GT, 95, or POS 02 modifiers) are allowable.

Measure Submission Type:

Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.


All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis

Denominator Criteria (Eligible Cases):
Patients aged ≥ 18 years on date of encounter


Diagnosis for chronic hepatitis C (ICD-10-CM): B18.2, B19.20, B19.21


Diagnosis for cirrhosis (ICD-10-CM): K70.30, K70.31, K74.60, K74.69


Patient encounter during the performance period (CPT): 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215


Patients who underwent abdominal imaging with either ultrasound, contrast enhanced CT or MRI

Numerator Options:

Performance Met:

Patient underwent abdominal imaging with ultrasound, contrast enhanced CT or contrast MRI for HCC (G9455)


Denominator Exception:

Documentation of medical or patient reason(s) for not ordering or performing screening for HCC. Medical reason: Comorbid medical conditions with expected survival <5 years, hepatic decompensation and not a candidate for liver transplantation, or other medical reasons. Patient reasons: Patient declined or other patient reasons (e.g., cost of tests, time related to accessing testing equipment) (G9456)


Performance Not Met:

Patient did not undergo abdominal imaging and did not have a documented reason for not undergoing abdominal imaging in the submission period (G9457)


CMS-Family-Medicine-2022, CMS-Gastro-enterology-2022, CMS-Internal-Medicine-2022, Gastroenterology-2022, General Practice/Family Medicine-2022, Geriatrics / Gerontology-2022, Infectious Disease-2022, Internal Medicine-2022, Lab Medicine-2022, Obstetrics/Gynecology-2022, Quality-2022, Telehealth-2022